秋水仙碱与单独常规治疗对COVID-19住院患者插管和28天死亡率的影响:一项随机临床试验
该多中心、开放标签、随机临床试验于2020年4月17日至2021年3月28日纳入1279例确诊或疑似SARS-CoV-2感染的住院成人患者,随机分为常规治疗组(639例)和秋水仙碱组(640例)。秋水仙碱口服负荷量1.5 mg,2小时内再给0.5 mg,随后0.5 mg每日两次,持续14天或至出院。主要复合终点(机械通气或28天死亡)在秋水仙碱组160例(25.0%),常规治疗组184例(28.8%)(HR 0.83;95%CI 0.67-1.02;P=0.08);28天死亡在秋水仙碱组131例(20.5%),常规治疗组142例(22.2%)(HR 0.88;95%CI 0.70-1.12)。结论认为秋水仙碱未显著降低机械通气或28天死亡率。
要点
- 在COVID-19肺炎住院患者中,秋水仙碱组机械通气或28天死亡复合终点发生率25.0%(160例),常规治疗组28.8%(184例),HR 0.83(95%CI 0.67-1.02;P=0.08),未达统计学显著。
- 秋水仙碱组28天死亡20.5%(131例),常规治疗组22.2%(142例),HR 0.88(95%CI 0.70-1.12),未达统计学显著。
- 秋水仙碱口服方案为负荷量1.5 mg,2小时内再给0.5 mg,随后0.5 mg每日两次,持续14天或至出院(以先发生者为准)。
- 秋水仙碱最常见的不良反应为腹泻,报告于68例(11.3%)患者。
- 研究纳入确诊或疑似SARS-CoV-2感染、因COVID-19症状住院且存在严重急性呼吸综合征或氧饱和度下降的成人患者;主要排除标准包括秋水仙碱明确适应证或禁忌证、慢性肾脏病、随机化前SARS-CoV-2逆转录聚合酶链反应检测阴性。
适用人群与场景
- 确诊或疑似SARS-CoV-2感染的成人住院患者,因COVID-19症状住院且存在严重急性呼吸综合征或氧饱和度下降。
- 主要排除标准:秋水仙碱明确适应证或禁忌证、慢性肾脏病、随机化前SARS-CoV-2逆转录聚合酶链反应检测阴性。
处置流程与药物剂量
- 秋水仙碱组:口服负荷量1.5 mg(随机化后立即),2小时内再口服0.5 mg,随后0.5 mg口服每日两次,持续14天或至出院(以先发生者为准)。
- 对照组:仅常规治疗。
研究设计与关键结果
- 多中心、开放标签、随机临床试验(COLCOVID),于2020年4月17日至2021年3月28日纳入1279例住院患者(平均[SD]年龄61.8[14.6]岁;女性449例[35.1%],男性830例[64.9%]),常规治疗组639例,秋水仙碱组640例;1171例(91.5%)使用皮质类固醇。
- 第一主要复合终点(28天时新需机械通气或死亡):秋水仙碱组160例(25.0%)vs 常规治疗组184例(28.8%),HR 0.83(95%CI 0.67-1.02;P=0.08)。
- 第二主要终点(28天死亡):秋水仙碱组131例(20.5%)vs 常规治疗组142例(22.2%),HR 0.88(95%CI 0.70-1.12)。
- 不良事件:腹泻为秋水仙碱最常见不良反应,报告于68例(11.3%)患者。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机临床试验。
- 结论:与常规治疗相比,秋水仙碱未显著降低COVID-19肺炎住院患者的机械通气或28天死亡率。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本研究结果不支持对COVID-19肺炎住院患者使用秋水仙碱以期降低机械通气或28天死亡率(作者结论:秋水仙碱未显著降低机械通气或28天死亡率)。
- 使用秋水仙碱时需注意腹泻,本研究中68例(11.3%)报告腹泻。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hospitalized patients with COVID-19 pneumonia have high rates of morbidity and mortality.
OBJECTIVE: To assess the efficacy of colchicine in hospitalized patients with COVID-19 pneumonia.
DESIGN, SETTING, AND PARTICIPANTS: The Estudios Clínicos Latino América (ECLA) Population Health Research Institute (PHRI) COLCOVID trial was a multicenter, open-label, randomized clinical trial performed from April 17, 2020, to March 28, 2021, in adults with confirmed or suspected SARS-CoV-2 infection followed for up to 28 days. Participants received colchicine vs usual care if they were hospitalized with COVID-19 symptoms and had severe acute respiratory syndrome or oxygen desaturation. The main exclusion criteria were clear indications or contraindications for colchicine, chronic kidney disease, and negative results on a reverse transcription-polymerase chain reaction test for SARS-CoV-2 before randomization. Data were analyzed from June 20 to July 25, 2021.
INTERVENTIONS: Patients were assigned in a 1:1 ratio to usual care or usual care plus colchicine. Colchicine was administered orally in a loading dose of 1.5 mg immediately after randomization, followed by 0.5 mg orally within 2 hours of the initial dose and 0.5 mg orally twice a day for 14 days or discharge, whichever occurred first.
MAIN OUTCOMES AND MEASURES: The first coprimary outcome was the composite of a new requirement for mechanical ventilation or death evaluated at 28 days. The second coprimary outcome was death at 28 days.
RESULTS: A total of 1279 hospitalized patients (mean [SD] age, 61.8 [14.6] years; 449 [35.1%] women and 830 [64.9%] men) were randomized, including 639 patients in the usual care group and 640 patients in the colchicine group. Corticosteroids were used in 1171 patients (91.5%). The coprimary outcome of mechanical ventilation or 28-day death occurred in 160 patients (25.0%) in the colchicine group and 184 patients (28.8%) in the usual care group (hazard ratio [HR], 0.83; 95% CI, 0.67-1.02; P = .08). The second coprimary outcome, 28-day death, occurred in 131 patients (20.5%) in the colchicine group and 142 patients (22.2%) in the usual care group (HR, 0.88; 95% CI, 0.70-1.12). Diarrhea was the most frequent adverse effect of colchicine, reported in 68 patients (11.3%).
CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04328480.
参考来源
- Diaz R, Orlandini A, Castellana N, et al. Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34964849. doi:10.1001/jamanetworkopen.2021.41328
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。